Review
BibTex RIS Cite

Çocukluk Çağı Aşıları ve Covid-19 Enfeksiyonu

Year 2023, Volume: 17 Issue: 1, 74 - 84, 30.01.2023
https://doi.org/10.12956/tchd.884410

Abstract

Coronavirus 2019 disease (COVİD-19) started in Wuhan/ China in December 2019 and turned into a global public health crisis in a short time and was accepted as a pandemic in March 2020. It can cause serious and fatal consequences, especially by involving the lungs. All over the world, ıt has been observed that children are less and mildly affected by this disease. Until an effective treatment or a special vaccine against COVID-19 was found, several clues were sought from this good prognosis of children. And various studies have been carried out by putting forward the hypothesis that childhood vaccines may have a protective effect. This is explained by the ‘trained immune response’ mechanism obtained from previous pandemics or the ‘cross protection’ shown in previous endemic diseases. But there are also opposing views that it is not effective. In this article, we will discuss the effects of alive vaccines MMR vaccines and BCG vaccines and inactive vaccines, influenza, hepatitis A and whooping cough vaccines, which are also included in the vaccination program of our country, on the development of immune response against COVID-19 and a direction for possible new pandemics in the future. The literature has been reviewed to be illustrative for this issue.The findings of the articles on this subject,all published in 2020, are summarized.

Supporting Institution

YOK

Project Number

YOK

References

  • 1. World Health Oragnization. Coranovirüs disease 2019 (COVİD-19) stiuation report-51. 11 March 2020. https://apps.who.int/iris/handle/10665/331475
  • 2. World Health Oragnization. COVİD-19 Weekly epidemiological Update. 24 November 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update---24-november-2020
  • 3.Carsetti R, Quintarelli C, Quinti I, Mortari EP, Zumla A, Ippolito G Locatelli F. The immune system of children: the key to understanding SARS-CoV-2 susceptibility? Lancet Child Adolescent Health. (2020) 4:414–6.
  • 4. Singh T, Hesto SM, Langel SN, Blasi M, Hurst JH, Fouda GG, et al. Lessons from COVID-19 in children: key hypotheses to guide preventative and therapeutic strategies. Clin Infect Dis. (2020) ciaa547; 71(8):2006-2013.
  • 5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica. (2020); 109:1088–95.
  • 6.Carozzi F, Provenzano S, Roth S. Urban density and COVID-19, discussion paper series, IZA Institure of Labor economics, (2020) IZA DP No. 13440
  • 7.Gold JE, Tilley LP, Baumgarts WH. MMR vaccine appears to coner strong protection from COVİD-19: Few deaths from SARS-COV-2 in highly vaccinated populations.Researchgate,2020 may29. DOI: 10.13140/RG.2.2.32128.25607
  • 8.Aaby P, Benn CS.Developing the concept of benefical non-spesific effects of live vaccines with epidemiological studies.Clin Microbiol İnfect.2019. 25:1459-1467.
  • 9.Moorlag S, Arts RJW, Van Crevel R, Netea MG.2019. Non spesific effects of BCG vaccine on viral infections. Clin Microbiaol İnfect.25:1473-1478.
  • 10. Aaby P, Benn CS, Flanagan KL, Klein SL, Kollmann TR, Lynn DJ, et al. The non-specific and sex-differential effects of vaccines. Nat Rev Immunol. (2020) 20:464–70.
  • 11.Aaby, P; Andersen, M; Sodemann, M; Jakobsen, M; Gomes, J; Fernandes, M Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age".BMJ. 1993; 307 (6915): 1308–11.
  • 12. Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines. 13 March 2014 WHO.https://www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf
  • 13. Shann F. The non-specific effects of vaccines. Arch Dis Childhood. (2010) 95:662–7. doi: 10.1136/archdischild-2015-310282
  • 14. Young A, Neumann B, Mendez RF. Homologous protein domains in SARS-COV-2 and measles,mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVİD-19. DOİ: 10.1101/2020.04.10.20053207
  • 15. Fidel PL, Noverr MC. Could an unrealted Live attenuated vaccine serve as a preventive measure to dampen septic inflmation associated with COVİD-19 Infection?.mBio.2000:11
  • 16. Sohrabi Y,Santos JCD, Dorenkamp M, Findeisen H, Godfrey R, Netea MG and et al. Trained immunity as a novel approach against COVİD-19 with a focus on Bacillus Calmette-Guerin vaccine: mechanisms, challanges and perspectives. Clinical & tranlational Immunology 2020; 9(12):e1228.
  • 17. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerrin induces NOD2-dependent non-spesific protection from reinfection via epigenetic reprogramming of monocytes. Proc.Natl. Acad.Sci.USA 109,17537-17542.
  • 18.Netea MG, Quintin J and van der Meer JW. Trained immunity:a memory for innate host defense. Cell Host Microbe 2011;9:355-361.
  • 19.Arts R JW, Carvalho A, La Rocca C, Palma C, Rodrigues F,Silvestre R. Immunometabolic pathways in BCG-induced trained immunity. 2016. Cell Reports 17,2562-2571.
  • 20.Mina MJ. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits. J.İnfect Disease.2017.74 Suppl 1:S10-S17.
  • 21.Biering-Sorensan S, Aaby P, Lund N.Early BCG-Denmark and neonatal mortality among infants weighing <2500 g:a randomised controlled trial. Clin Inf Dis 65:1183-1190.
  • 22. Welsh RM, Lisia KS, Szomolanyi-Tsuda E. Immunological memory to viral infections. Annu.Rev.Immunol.2004.22:711-43
  • 23. Ismail MB, Omari S, Rafei R, Dabboussi F,Hamze M. Covid-19 in children:Could pertusis vaccine play the protective role? .Medical Hypotheses.14145:110305.
  • 24.Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARSCoV-2 pandemic? Allergy 2020; 75: 1815–1819.
  • 25. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA 2020; 117: 17720–17726.
  • 26. Pereira M, Paixao E, Trajman A, Souza RA, Natividade MS, Pescraini JM and et al. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19. Respir Res 2020; 21: 178
  • 27. Ventura L, Vitali M, Romano Spica V. BCG vaccination and socioeconomic variables vs COVID-19 global features: clearing up a controversial issue. Allergy 2020. https://doi.org/10.1111/all.14524. Online ahead of print.
  • 28. Ozdemir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination effecting the spread and severity of COVID-19? Allergy 2020; 75: 1824–1827.
  • 29. Weng CH, Saal A, Butt WW, Bica N, Fisher JQ, Tao J et al. Bacillus CalmetteGuerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study. Epidemiol Infect 2020; 148: e140.
  • 30. Moorlag SJCFM, van Deuren RC, van Werkhoven CH , Jaeger M, Debisarun P, Taks Esther et al. Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study. Cell Rep Med 2020; 1: 100073.
  • 31. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y,Otazu GH. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. MedRvix. doi: https://doi.org/10.1101/2020.03.24.20042937
  • 32. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine-induced protection from COVID-19 infection, wishful thinking or a game changer?.medRxiv. 2020 May 12;2020.05.05.20091975. doi: 10.1101/2020.05.05.20091975.
  • 33. Shet A,Ray D, Malavige N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. MedRvix.doi: https://doi.org/10.1101/2020.04.01.20049478
  • 34. Kinoshita M, Tanaka M. Impact of routine infant BCG vaccination in young generation on prevention of local COVID-19 spread in Japan. J Infect 2020; 81: 625– 633
  • 35.Sohrabi Y, Santos JCD,Dorenkamp M and et al. Trained immunity as a novel approach against COVİD-19 with a focus on bacillus-calmette-guerin vaccine:mechanisms,challanges and perspectives.Clinical &translational Immunology.2020.9(12):e1228.
  • 36. O’Neil LA, Netea MG.BCG-induced trained immunity: can it offer protection against COVİD-19?. Nat Rev Immunol.2020:1-3.
  • 37. Mehta P,McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVİD-19:consider cytokine storm syndromes and immunosuppression.Lancet.2020;395:1033-1034
  • 38. Hamiel U, Kozer E, Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA 2020; 323: 2340–2341
  • 39. Parades CF, Ghandhnoosh N, Latif Hassan. Decarceration and community reentry in the COVİD-19 era. Lancet 2021.volume 21.E11-16.
  • 40. Hensel J , McAndrews KM, McGrail DJ. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci Rep. 2020 Oct 27;10(1):18377
  • 41. Allam MF, Amin GE. BCG vaccine does not protect against COVİD-19. The open respiratory medicine journal. 2020;14: 45–46.
  • 42. Asahara M. The effect of BCG vaccination on COVİD-19 examined by a statistical approach: no positive results from the Diamonnd Princess and cross national differences previously reported by worldwide comparisions are flawed in several ways.medRxiv.2020.DOI: 10.1101/2020.04.17.20068601
  • 43. Anand Anbarasu, Sudha Ramaiah & Paul Livingstone. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?. Hum Vaccin Immonther.2020:1;16(9):2217-2218
  • 44. Islam N, Khunti K, Majeed A.COVID-19, seasonal influenza and measles: potential triple burden and the role of flu and MMR vaccines. J R Soc Med. 2020 Dec;113(12):485-486.
  • 45. Sidiq KR, Sabir DK, Ali SM. Does Early Childhood Vaccination Protect Against COVID-19?. Front Mol Biosci. 2020 Jun 5;7:120.
  • 46. Gold JE, Baumgartl WH, Okyay RA. Analysis of measles-mumps-rubella (MMR) titers of recovered COVİD-19 patients.mBio.2020. DOI: 10.1128/mBio.02628-20
  • 47.Larenas-Linnemann DE, Rodrigues-Monroy.Thirty‐six COVID‐19 cases preventively vaccinated with mumps‐measles‐rubella vaccine: All mild course.Allergy.2020.DOI: 10.1111/all.14584
  • 48.(https://www.globenewswire.com/newsrelease/2020/05/01/2026166/0/en/MMR-Vaccine-May-Reduce-COVID-19-Hospitalization-Rate-According-to-World-Organization.html)
  • 49.Sanjay Deshpande Sarath Balaji . MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?.indian pediatr. 2020 Aug 15;57(8):773.
  • 50.Özdemir Ö.Measles-Mumps-Rubella Vaccine and COVID-19 Relationship.mBio. 2020;11(5):e01832-20.
  • 51. WHO SAGE Seasonal Influenza Vaccination Recommendations during the COVİD-19 Pandemic-Interim guidence.21 september 2020.
  • 52. Yue H, Zhang M, Xing L,et al.The epidemiology and clinical characteristics of co-infection of SARS-COV-2 and influenza viruses in patients durin COVİD-19 out break. J Med Virology.2020;92:2870-2873.
  • 53. Thindwa D, Queseda MG, Liu Yang.Use of seasonal influenza and pneumococcal polysaccharide vaccines in older aduts to reduce COVİD-19 mortality. Vaccine 2020;38(34):5398-5401
  • 54.Ragni P, Marino M, Formisano D.Association between exposure to influenza vaccination and COVİD-19 diagnosis and outcomes.Vaccines.2020;8(4):675.
  • 55. Amato M, W erba JP, Frigerio B and et al. Relationship between influenza vaccination coverage rate and COVİD-19 Outbreak:An Italian ecological study. Vaccines(Basel) 2020.16;8:535
  • 56. Massoudi N, Mohit B. A case- control study of the 2019 influenza vaccine and incidance of COVİD-19 Among healthcare workers. J.Clin İMMUNOL.2020.1-11.
  • 57.Sarıalioğlu F, Belen apak FB, Haberal M. Can hepatitis A Vaccine provide protection against COVİD-19?.Exp Clin Transplant.2020.18:141-143
  • 58.Kuramoto I, Fujiyama S, Matsushita K, Sato T. Immune response after hepatitis A vaccination in hemodialysis patients: Comparison with hepatitis B vaccination. J Gastroenterol Hepatol 1994; 9: 228–231

Childhood Vaccines and Covid-19 Infection

Year 2023, Volume: 17 Issue: 1, 74 - 84, 30.01.2023
https://doi.org/10.12956/tchd.884410

Abstract

Coronavirus 2019 disease (COVİD-19) started in Wuhan/ China in December 2019 and turned into a global public health crisis in a short time and was accepted as a pandemic in March 2020. It can cause serious and fatal consequences, especially by involving the lungs. All over the world, ıt has been observed that children are less and mildly affected by this disease. Until an effective treatment or a special vaccine against COVID-19 was found, several clues were sought from this good prognosis of children. And various studies have been carried out by putting forward the hypothesis that childhood vaccines may have a protective effect. This is explained by the ‘trained immune response’ mechanism obtained from previous pandemics or the ‘cross protection’ shown in previous endemic diseases. But there are also opposing views that it is not effective. In this article, we will discuss the effects of alive vaccines MMR vaccines and BCG vaccines and inactive vaccines, influenza, hepatitis A and whooping cough vaccines, which are also included in the vaccination program of our country, on the development of immune response against COVID-19 and a direction for possible new pandemics in the future. The literature has been reviewed to be illustrative for this issue.The findings of the articles on this subject,all published in 2020, are summarized.

Project Number

YOK

References

  • 1. World Health Oragnization. Coranovirüs disease 2019 (COVİD-19) stiuation report-51. 11 March 2020. https://apps.who.int/iris/handle/10665/331475
  • 2. World Health Oragnization. COVİD-19 Weekly epidemiological Update. 24 November 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update---24-november-2020
  • 3.Carsetti R, Quintarelli C, Quinti I, Mortari EP, Zumla A, Ippolito G Locatelli F. The immune system of children: the key to understanding SARS-CoV-2 susceptibility? Lancet Child Adolescent Health. (2020) 4:414–6.
  • 4. Singh T, Hesto SM, Langel SN, Blasi M, Hurst JH, Fouda GG, et al. Lessons from COVID-19 in children: key hypotheses to guide preventative and therapeutic strategies. Clin Infect Dis. (2020) ciaa547; 71(8):2006-2013.
  • 5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica. (2020); 109:1088–95.
  • 6.Carozzi F, Provenzano S, Roth S. Urban density and COVID-19, discussion paper series, IZA Institure of Labor economics, (2020) IZA DP No. 13440
  • 7.Gold JE, Tilley LP, Baumgarts WH. MMR vaccine appears to coner strong protection from COVİD-19: Few deaths from SARS-COV-2 in highly vaccinated populations.Researchgate,2020 may29. DOI: 10.13140/RG.2.2.32128.25607
  • 8.Aaby P, Benn CS.Developing the concept of benefical non-spesific effects of live vaccines with epidemiological studies.Clin Microbiol İnfect.2019. 25:1459-1467.
  • 9.Moorlag S, Arts RJW, Van Crevel R, Netea MG.2019. Non spesific effects of BCG vaccine on viral infections. Clin Microbiaol İnfect.25:1473-1478.
  • 10. Aaby P, Benn CS, Flanagan KL, Klein SL, Kollmann TR, Lynn DJ, et al. The non-specific and sex-differential effects of vaccines. Nat Rev Immunol. (2020) 20:464–70.
  • 11.Aaby, P; Andersen, M; Sodemann, M; Jakobsen, M; Gomes, J; Fernandes, M Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age".BMJ. 1993; 307 (6915): 1308–11.
  • 12. Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines. 13 March 2014 WHO.https://www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf
  • 13. Shann F. The non-specific effects of vaccines. Arch Dis Childhood. (2010) 95:662–7. doi: 10.1136/archdischild-2015-310282
  • 14. Young A, Neumann B, Mendez RF. Homologous protein domains in SARS-COV-2 and measles,mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVİD-19. DOİ: 10.1101/2020.04.10.20053207
  • 15. Fidel PL, Noverr MC. Could an unrealted Live attenuated vaccine serve as a preventive measure to dampen septic inflmation associated with COVİD-19 Infection?.mBio.2000:11
  • 16. Sohrabi Y,Santos JCD, Dorenkamp M, Findeisen H, Godfrey R, Netea MG and et al. Trained immunity as a novel approach against COVİD-19 with a focus on Bacillus Calmette-Guerin vaccine: mechanisms, challanges and perspectives. Clinical & tranlational Immunology 2020; 9(12):e1228.
  • 17. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerrin induces NOD2-dependent non-spesific protection from reinfection via epigenetic reprogramming of monocytes. Proc.Natl. Acad.Sci.USA 109,17537-17542.
  • 18.Netea MG, Quintin J and van der Meer JW. Trained immunity:a memory for innate host defense. Cell Host Microbe 2011;9:355-361.
  • 19.Arts R JW, Carvalho A, La Rocca C, Palma C, Rodrigues F,Silvestre R. Immunometabolic pathways in BCG-induced trained immunity. 2016. Cell Reports 17,2562-2571.
  • 20.Mina MJ. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits. J.İnfect Disease.2017.74 Suppl 1:S10-S17.
  • 21.Biering-Sorensan S, Aaby P, Lund N.Early BCG-Denmark and neonatal mortality among infants weighing <2500 g:a randomised controlled trial. Clin Inf Dis 65:1183-1190.
  • 22. Welsh RM, Lisia KS, Szomolanyi-Tsuda E. Immunological memory to viral infections. Annu.Rev.Immunol.2004.22:711-43
  • 23. Ismail MB, Omari S, Rafei R, Dabboussi F,Hamze M. Covid-19 in children:Could pertusis vaccine play the protective role? .Medical Hypotheses.14145:110305.
  • 24.Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARSCoV-2 pandemic? Allergy 2020; 75: 1815–1819.
  • 25. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA 2020; 117: 17720–17726.
  • 26. Pereira M, Paixao E, Trajman A, Souza RA, Natividade MS, Pescraini JM and et al. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19. Respir Res 2020; 21: 178
  • 27. Ventura L, Vitali M, Romano Spica V. BCG vaccination and socioeconomic variables vs COVID-19 global features: clearing up a controversial issue. Allergy 2020. https://doi.org/10.1111/all.14524. Online ahead of print.
  • 28. Ozdemir C, Kucuksezer UC, Tamay ZU. Is BCG vaccination effecting the spread and severity of COVID-19? Allergy 2020; 75: 1824–1827.
  • 29. Weng CH, Saal A, Butt WW, Bica N, Fisher JQ, Tao J et al. Bacillus CalmetteGuerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study. Epidemiol Infect 2020; 148: e140.
  • 30. Moorlag SJCFM, van Deuren RC, van Werkhoven CH , Jaeger M, Debisarun P, Taks Esther et al. Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study. Cell Rep Med 2020; 1: 100073.
  • 31. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y,Otazu GH. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. MedRvix. doi: https://doi.org/10.1101/2020.03.24.20042937
  • 32. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine-induced protection from COVID-19 infection, wishful thinking or a game changer?.medRxiv. 2020 May 12;2020.05.05.20091975. doi: 10.1101/2020.05.05.20091975.
  • 33. Shet A,Ray D, Malavige N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. MedRvix.doi: https://doi.org/10.1101/2020.04.01.20049478
  • 34. Kinoshita M, Tanaka M. Impact of routine infant BCG vaccination in young generation on prevention of local COVID-19 spread in Japan. J Infect 2020; 81: 625– 633
  • 35.Sohrabi Y, Santos JCD,Dorenkamp M and et al. Trained immunity as a novel approach against COVİD-19 with a focus on bacillus-calmette-guerin vaccine:mechanisms,challanges and perspectives.Clinical &translational Immunology.2020.9(12):e1228.
  • 36. O’Neil LA, Netea MG.BCG-induced trained immunity: can it offer protection against COVİD-19?. Nat Rev Immunol.2020:1-3.
  • 37. Mehta P,McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVİD-19:consider cytokine storm syndromes and immunosuppression.Lancet.2020;395:1033-1034
  • 38. Hamiel U, Kozer E, Youngster I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA 2020; 323: 2340–2341
  • 39. Parades CF, Ghandhnoosh N, Latif Hassan. Decarceration and community reentry in the COVİD-19 era. Lancet 2021.volume 21.E11-16.
  • 40. Hensel J , McAndrews KM, McGrail DJ. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci Rep. 2020 Oct 27;10(1):18377
  • 41. Allam MF, Amin GE. BCG vaccine does not protect against COVİD-19. The open respiratory medicine journal. 2020;14: 45–46.
  • 42. Asahara M. The effect of BCG vaccination on COVİD-19 examined by a statistical approach: no positive results from the Diamonnd Princess and cross national differences previously reported by worldwide comparisions are flawed in several ways.medRxiv.2020.DOI: 10.1101/2020.04.17.20068601
  • 43. Anand Anbarasu, Sudha Ramaiah & Paul Livingstone. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?. Hum Vaccin Immonther.2020:1;16(9):2217-2218
  • 44. Islam N, Khunti K, Majeed A.COVID-19, seasonal influenza and measles: potential triple burden and the role of flu and MMR vaccines. J R Soc Med. 2020 Dec;113(12):485-486.
  • 45. Sidiq KR, Sabir DK, Ali SM. Does Early Childhood Vaccination Protect Against COVID-19?. Front Mol Biosci. 2020 Jun 5;7:120.
  • 46. Gold JE, Baumgartl WH, Okyay RA. Analysis of measles-mumps-rubella (MMR) titers of recovered COVİD-19 patients.mBio.2020. DOI: 10.1128/mBio.02628-20
  • 47.Larenas-Linnemann DE, Rodrigues-Monroy.Thirty‐six COVID‐19 cases preventively vaccinated with mumps‐measles‐rubella vaccine: All mild course.Allergy.2020.DOI: 10.1111/all.14584
  • 48.(https://www.globenewswire.com/newsrelease/2020/05/01/2026166/0/en/MMR-Vaccine-May-Reduce-COVID-19-Hospitalization-Rate-According-to-World-Organization.html)
  • 49.Sanjay Deshpande Sarath Balaji . MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?.indian pediatr. 2020 Aug 15;57(8):773.
  • 50.Özdemir Ö.Measles-Mumps-Rubella Vaccine and COVID-19 Relationship.mBio. 2020;11(5):e01832-20.
  • 51. WHO SAGE Seasonal Influenza Vaccination Recommendations during the COVİD-19 Pandemic-Interim guidence.21 september 2020.
  • 52. Yue H, Zhang M, Xing L,et al.The epidemiology and clinical characteristics of co-infection of SARS-COV-2 and influenza viruses in patients durin COVİD-19 out break. J Med Virology.2020;92:2870-2873.
  • 53. Thindwa D, Queseda MG, Liu Yang.Use of seasonal influenza and pneumococcal polysaccharide vaccines in older aduts to reduce COVİD-19 mortality. Vaccine 2020;38(34):5398-5401
  • 54.Ragni P, Marino M, Formisano D.Association between exposure to influenza vaccination and COVİD-19 diagnosis and outcomes.Vaccines.2020;8(4):675.
  • 55. Amato M, W erba JP, Frigerio B and et al. Relationship between influenza vaccination coverage rate and COVİD-19 Outbreak:An Italian ecological study. Vaccines(Basel) 2020.16;8:535
  • 56. Massoudi N, Mohit B. A case- control study of the 2019 influenza vaccine and incidance of COVİD-19 Among healthcare workers. J.Clin İMMUNOL.2020.1-11.
  • 57.Sarıalioğlu F, Belen apak FB, Haberal M. Can hepatitis A Vaccine provide protection against COVİD-19?.Exp Clin Transplant.2020.18:141-143
  • 58.Kuramoto I, Fujiyama S, Matsushita K, Sato T. Immune response after hepatitis A vaccination in hemodialysis patients: Comparison with hepatitis B vaccination. J Gastroenterol Hepatol 1994; 9: 228–231
There are 58 citations in total.

Details

Primary Language Turkish
Subjects ​Internal Diseases
Journal Section REVIEW
Authors

Şule Büyük Yaytokgil 0000-0002-9393-7497

Muge Toyran 0000-0002-2490-0551

Project Number YOK
Publication Date January 30, 2023
Submission Date February 21, 2021
Published in Issue Year 2023 Volume: 17 Issue: 1

Cite

Vancouver Büyük Yaytokgil Ş, Toyran M. Çocukluk Çağı Aşıları ve Covid-19 Enfeksiyonu. Türkiye Çocuk Hast Derg. 2023;17(1):74-8.


The publication language of Turkish Journal of Pediatric Disease is English.


Manuscripts submitted to the Turkish Journal of Pediatric Disease will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in the field, in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions. Articles accepted for publication in the Turkish Journal of Pediatrics are put in the order of publication, with at least 10 original articles in each issue, taking into account the acceptance dates. If the articles sent to the reviewers for evaluation are assessed as a senior for publication by the reviewers, the section editor and the editor considering all aspects (originality, high scientific quality and citation potential), it receives publication priority in addition to the articles assigned for the next issue.


The aim of the Turkish Journal of Pediatrics is to publish high-quality original research articles that will contribute to the international literature in the field of general pediatric health and diseases and its sub-branches. It also publishes editorial opinions, letters to the editor, reviews, case reports, book reviews, comments on previously published articles, meeting and conference proceedings, announcements, and biography. In addition to the field of child health and diseases, the journal also includes articles prepared in fields such as surgery, dentistry, public health, nutrition and dietetics, social services, human genetics, basic sciences, psychology, psychiatry, educational sciences, sociology and nursing, provided that they are related to this field. can be published.